For its second fiscal quarter (ending June 30), Bio-Rad Laboratories Inc (NYSE: BIO) has reported E.P.S. of $-76.26 compared to $-39.59 a year ago. For the latest four quarters through June 30, E.P.S. were $-46.81 versus $-14.68 for the same period a year ago.
Recent Price Action
Bio-Rad Laboratories Inc (NYSE: BIO) stock rose modestly by 0.9% on 8/1/24. The stock closed at $341.25. Trading volume in this advance was normal. The stock has been weak relative to the market over the last nine months but has risen 10.1% during the last week.
Current PriceTarget Research Rating
BIO is expected to be a modest Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
Bio-Rad Laboratories has a current Value Trend Rating of C (Low Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Bio-Rad Laboratories has a good Appreciation Score of 77 but a poor Power Rating of 16, resulting in the Low Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment